COMPASSION‑16 Phase III data show that adding cadonilimab to first‑line chemotherapy, with or without bevacizumab, improved outcomes in advanced cervical cancer, according to the trial investigators. The multicenter study reported statistically meaningful benefits in key efficacy measures versus standard therapy, positioning cadonilimab as a potential new immunotherapy option in a hard‑to‑treat indication. Cadonilimab is a bispecific PD‑1/CTLA‑4 targeting agent; bispecific checkpoint modulators aim to simultaneously engage multiple inhibitory pathways to boost antitumor immunity. The result will steer development and partnering decisions for companies carrying cadonilimab and will likely influence treatment guidelines if confirmed in regulatory submissions and peer‑reviewed publications.